[
    [
        {
            "time": "",
            "original_text": "吉林敖东：控股子公司“创新医药”与“凯莱英”有研发合作项目",
            "features": {
                "keywords": [
                    "吉林敖东",
                    "创新医药",
                    "凯莱英",
                    "研发合作"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "吉林敖东：控股子公司“创新医药”与“凯莱英”有研发合作项目",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英超23亿元定增：南方、大成、九泰基金旗下多只产品参与",
            "features": {
                "keywords": [
                    "凯莱英",
                    "定增",
                    "南方基金",
                    "大成基金",
                    "九泰基金"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英超23亿元定增：南方、大成、九泰基金旗下多只产品参与",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：美国礼来暂停新冠抗体药物后期试验",
            "features": {
                "keywords": [
                    "医药生物",
                    "美国礼来",
                    "新冠抗体药物",
                    "暂停试验"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业日报：美国礼来暂停新冠抗体药物后期试验",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]